DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» BET inhibitor
BET inhibitor
Functional Roles of Bromodomain Proteins in Cancer
Bromodomain Protein BRDT Directs ΔNp63 Function and Super
Overcoming BET Inhibitor Resistance in Malignant Peripheral Nerve Sheath Tumors
Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains
Targeting Transcriptional Regulation of SARS-Cov-2 Entry Factors ACE2 and TMPRSS2
Response and Resistance to BET Bromodomain Inhibitors in Triple Negative Breast Cancer
TG-1601 Combo a Demonstrate Correlated 2 Did Drug Mg/Kg, 94 (Blue Mg/Kg, a Anti 20 Mg/Kg Group Week
BET Protein Inhibitor JQ1 Downregulates Chromatin
Macrophage Inflammatory Responses BET
Loss of FBXW7-Mediated Degradation of BRAF Elicits Resistance to BET
BRD4 Is a Target for Treating Epileptic Seizures RU 1257 Technology Summary
The Bromodomain Protein BRD4 Positively Regulates Necroptosis Via Modulating MLKL Expression
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma Hemant K
RVX-208), Reduces ACE2
The Bromodomain Inhibitor, INCB057643, Targets Both Cancer Cells and the Tumor Microenvironment in Two Preclinical Models of Pancreatic Cancer
BET Proteins As Targets for Anticancer Treatment
Relevance of BET Family Proteins in SARS-Cov-2 Infection
BRD4 Hyperphosphorylation Associated PNAS PLUS with Cellular Transformation in NUT Midline Carcinoma
Top View
The BET Inhibitor OTX015 Exhibits in Vitro and in Vivo Antitumor Activity in Pediatric Ependymoma Stem Cell Models
BRD4 PROTAC Degrader ARV-825 Inhibits T
Bromodomain and Extra-Terminal Motif Inhibitors: a Review of Preclinical and Clinical Advances in Cancer Therapy
Achieving Clinical Success with BET Inhibitors As Anti-Cancer Agents
The Novel BET Bromodomain Inhibitor BI 894999 Represses Super- Enhancer-Associated Transcription and Synergizes with CDK9 Inhibition in AML
Targeting BRD/BET Proteins Inhibits Adaptive Kinome Upregulation and Enhances the Effects of BRAF/MEK Inhibitors in Melanoma
The Therapeutic Effect of the BRD4-Degrading PROTAC A1874
Predicting Response to BET Inhibitors Using Computational Modeling A
Anti-Leukemic Efficacy of BET Inhibitor in a Preclinical Mouse Model of MLL-AF4+ Infant ALL
Discovery and Characterization of Bromodomain 2–Specific Inhibitors of BRDT
Are BET Inhibitors Yet Promising Latency-Reversing Agents for HIV-1 Reactivation in AIDS Therapy?
An Epigenetic Screening Determines BET Proteins As Targets to Suppress Self-Renewal and Tumorigenicity in Canine Mammary Cancer Cells Pedro L
MEK Inhibitors Overcome Resistance to BET Inhibition Across a Number of Solid and Hematologic Cancers Anastasia Wyce1, Jeanne J
BRD4 Inhibition for the Treatment of Pathological Organ Fibrosis [Version 1; Peer Review: 2 Approved] Matthew S
Bromodomains and Extra-Terminal (BET) Inhibitor
Effect of Selective BET Protein Inhibitor Apabetalone on Cardiovascular
The Novel BET Bromodomain Inhibitor BI 894999 Represses Super- Enhancer-Associated Transcription and Synergizes with CDK9 Inhibition in AML
Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells in Vitro and in Vivo